← FDA DRUG APPROVALS

FDA ANDA · ANDA210465

LANSOPRAZOLE

Sponsor: DR REDDYS

APPLICATION
ANDA210465
TYPE
ANDA
ORIGINAL APPROVAL
2021-02-01
LATEST ACTION
2023-09-19
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

LANSOPRAZOLEPrescription
LANSOPRAZOLE 15MG · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE · ORAL
LANSOPRAZOLEPrescription
LANSOPRAZOLE 30MG · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE · ORAL

Approval history

2023-09-19Labeling · Supplement 3 · standardAP
2023-09-19Labeling · Supplement 1 · standardAP
2021-02-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →